stoxline Quote Chart Rank Option Currency Glossary
  
Pasithea Therapeutics Corp. (KTTA)
2.67  -0.16 (-5.65%)    12-12 16:00
Open: 2.89
High: 2.89
Volume: 20,609
  
Pre. Close: 2.83
Low: 2.63
Market Cap: 3(M)
Technical analysis
2024-12-13 7:47:33 AM
Short term     
Mid term     
Targets 6-month :  3.93 1-year :  4.47
Resists First :  3.37 Second :  3.82
Pivot price 2.94
Supports First :  2.63 Second :  2.18
MAs MA(5) :  2.84 MA(20) :  3.02
MA(100) :  4.2 MA(250) :  5.71
MACD MACD :  -0.3 Signal :  -0.3
%K %D K(14,3) :  11.6 D(3) :  20.1
RSI RSI(14): 32.7
52-week High :  9.39 Low :  2.63
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ KTTA ] has closed below the lower bollinger band by 1.2%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ KTTA ] is to continue within current trading range. It is unclear right now based on current values. 62.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.9 - 2.91 2.91 - 2.93
Low: 2.59 - 2.61 2.61 - 2.63
Close: 2.64 - 2.67 2.67 - 2.7
Company Description

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Headline News

Wed, 20 Nov 2024
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - GlobeNewswire

Wed, 20 Nov 2024
Pasithea's PAS-004 Drug Shows Strong Safety Profile in Phase 1 Trial, Zero Toxicity Issues | KTTA Stock News - StockTitan

Mon, 04 Nov 2024
Interview with the CEO: Pasithea Therapeutics Corp. (NASDAQ:KTTA) - The Wall Street Transcript

Thu, 26 Sep 2024
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - GlobeNewswire

Thu, 26 Sep 2024
Biotech Stock Pasithea Therapeutics Corp. (NASDAQ: KTTA) Soars on Positive Data from Phase 1 Clinical Trials - Investorideas.com newswire

Thu, 26 Sep 2024
Pasithea Therapeutics : Investor Presentation - Marketscreener.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 1 (M)
Shares Float 1 (M)
Held by Insiders 23.1 (%)
Held by Institutions 2.8 (%)
Shares Short 12 (K)
Shares Short P.Month 171 (K)
Stock Financials
EPS -14.79
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 22.45
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -38 %
Return on Equity (ttm) -63.3 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -12.82
Qtrly Earnings Growth 0 %
Operating Cash Flow -15 (M)
Levered Free Cash Flow -9 (M)
Stock Valuations
PE Ratio -0.19
PEG Ratio 0
Price to Book value 0.11
Price to Sales 0
Price to Cash Flow -0.23
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android